Level Biotechnology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Level Biotechnology.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Healthcare earnings growth | 18.8% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Some Investors May Be Worried About Level Biotechnology's (GTSM:3118) Returns On Capital
Apr 27Calculating The Fair Value Of Level Biotechnology Inc. (GTSM:3118)
Mar 16Here's What You Should Know About Level Biotechnology Inc.'s (GTSM:3118) 3.6% Dividend Yield
Feb 14Does Level Biotechnology's (GTSM:3118) Returns On Capital Reflect Well On The Business?
Jan 24Level Biotechnology Inc.'s (GTSM:3118) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Jan 03Calculating The Intrinsic Value Of Level Biotechnology Inc. (GTSM:3118)
Dec 16Here's Why We Think Level Biotechnology's (GTSM:3118) Statutory Earnings Might Be Conservative
Nov 28In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Level Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2024 | 697 | 62 | 49 | 54 | N/A |
3/31/2024 | 695 | 66 | 50 | 57 | N/A |
12/31/2023 | 661 | 63 | 63 | 70 | N/A |
9/30/2023 | 654 | 60 | 67 | 74 | N/A |
6/30/2023 | 633 | 62 | 70 | 76 | N/A |
3/31/2023 | 620 | 64 | 56 | 64 | N/A |
12/31/2022 | 593 | 58 | 58 | 65 | N/A |
9/30/2022 | 569 | 57 | 75 | 82 | N/A |
6/30/2022 | 601 | 62 | 97 | 104 | N/A |
3/31/2022 | 632 | 61 | 135 | 145 | N/A |
12/31/2021 | 677 | 68 | 147 | 156 | N/A |
9/30/2021 | 728 | 74 | 117 | 127 | N/A |
6/30/2021 | 716 | 70 | 114 | 123 | N/A |
3/31/2021 | 701 | 69 | 101 | 104 | N/A |
12/31/2020 | 672 | 58 | 81 | 83 | N/A |
9/30/2020 | 648 | 50 | 99 | 101 | N/A |
6/30/2020 | 641 | 48 | 84 | 86 | N/A |
3/31/2020 | 635 | 47 | 80 | 83 | N/A |
12/31/2019 | 639 | 47 | 107 | 109 | N/A |
9/30/2019 | 646 | 47 | 127 | 129 | N/A |
6/30/2019 | 651 | 45 | 68 | 70 | N/A |
3/31/2019 | 644 | 41 | 59 | 60 | N/A |
12/31/2018 | 629 | 39 | 24 | 27 | N/A |
9/30/2018 | 619 | 46 | 4 | 10 | N/A |
6/30/2018 | 579 | 45 | 23 | 33 | N/A |
3/31/2018 | 583 | 57 | N/A | 31 | N/A |
12/31/2017 | 578 | 68 | N/A | 71 | N/A |
9/30/2017 | 543 | 72 | N/A | 48 | N/A |
6/30/2017 | 537 | 75 | N/A | 74 | N/A |
3/31/2017 | 512 | 65 | N/A | 87 | N/A |
12/31/2016 | 514 | 63 | N/A | 79 | N/A |
9/30/2016 | 504 | 61 | N/A | 101 | N/A |
6/30/2016 | 523 | 69 | N/A | 102 | N/A |
3/31/2016 | 530 | 78 | N/A | 109 | N/A |
12/31/2015 | 520 | 78 | N/A | 98 | N/A |
9/30/2015 | 540 | 85 | N/A | 104 | N/A |
6/30/2015 | 524 | 80 | N/A | 105 | N/A |
3/31/2015 | 526 | 77 | N/A | 110 | N/A |
12/31/2014 | 533 | 77 | N/A | 102 | N/A |
9/30/2014 | 515 | 71 | N/A | 117 | N/A |
6/30/2014 | 535 | 70 | N/A | 92 | N/A |
3/31/2014 | 527 | 66 | N/A | 92 | N/A |
12/31/2013 | 529 | 65 | N/A | 96 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 3118's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 3118's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 3118's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 3118's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 3118's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 3118's Return on Equity is forecast to be high in 3 years time